Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 5218SC

5218SC 50 µg (With Carrier) $199.00
5218SF 50 µg (Carrier Free) $199.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human NRG-1 (hNRG-1) Thr176-Lys238 (Accession #NP_001153480) was produced in E. coli cells at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hNRG-1. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hNRG-1 does not have a Met on the amino terminus and has a calculated MW of 7,284. DTT-reduced and non-reduced protein migrate as 6 kDa polypeptides. The expected amino-terminal TSHLV of recombinant hNRG-1 was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hNRG-1 was determined in a cell proliferation assay using MCF7 cells. The ED50 of each lot is between 1-4 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hNRG-1.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hNRG-1. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

NRG-1, a member of the EGF family, is involved in heart, mammary and nervous system development (1). NRG-1 is expressed by mammary epithelial, vascular endothelial and neuronal cells (2,3). At least 15 NRG-1 splice variants are known (1). These variants differ in EGF domains (α or β variants), amino-terminal splicing sites, and incorporation of exons encoding integral membrane regions (1). NRG-1 can induce or inhibit the proliferation of cells derived from breast cancer. The differences in effects of NRG-1 appear to depend on splice variation and interaction with receptor(s) (2). NRG-1 binds to ErbB3/HER3 or ErbB4/HER4. Binding induces dimerization with ErB2/HER2. The Akt, Erk1/2 and Erk5 pathways have been shown to participate in NRG-1 activated signaling (4,5). NRG-1 appears to have roles in schizophrenia and breast cancer (1,4,6).


1.  Falls, D.L. (2003) Exp Cell Res 284, 14-30.

2.  Chua, Y.L. et al. (2009) Oncogene 28, 4041-52.

3.  Kalinowski, A. et al. (2010) FASEB J 24, 2567-75.

4.  Montero, J.C. et al. (2008) Clin Cancer Res 14, 3237-41.

5.  Grossmann, K.S. et al. (2009) Proc Natl Acad Sci U S A 106, 16704-9.

6.  Mei, L. and Xiong, W.C. (2008) Nat Rev Neurosci 9, 437-52.


Entrez-Gene Id 3084
Swiss-Prot Acc. Q02297


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.